Enochian Biosciences, Inc. (ENOB)
Enochian Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $0.71, up 1.79% on the session, giving a market capitalisation of $45.4M. On trailing twelve-month figures it carries a trailing P/E of -0.88, a net margin of 0.0%. Its beta of 0.94 implies it has historically moved less than the broad market.
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
Enochian Biosciences, Inc. is most often compared with the following Healthcare names: